RIO DE JANEIRO, BRAZIL - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca AZN.L and Oxford University had died but added that the trial would continue.
Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment “there have been no concerns about safety of the clinical trial.”
A source familiar with the matter told Reuters that the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine, suggesting the person was part of the control . . .